From Dispensing Someone Else's Brand to Creating Your Own

Two practice models, very different roles

This guide is for the practitioner sitting at the transition. You have been stocking another brand's product for years. Patients trust your recommendation. The question is whether to graduate from dispensing to creating, and what changes when you do.

What changes: your relationship with the manufacturer

When you dispense a third-party brand, you purchase from the manufacturer (or, more often, from a distribution platform that sits between you and the manufacturer). You pay wholesale. You take a margin. You do not control the formula. You do not control packaging. You do not control whether the brand changes ingredients or discontinues a SKU.

When you create your own brand, you still purchase from the manufacturer, but you are at a different point in their workflow. You are buying production capacity, not finished branded inventory. You provide the formula (private labelPrivate LabelPre-made supplement formulas that a brand can sell under its own label. catalog selection or custom specification). You provide the label and packaging design. You absorb the inventory until your patients purchase it. You set the retail price.

The trade-off is direct. You take on more capital risk and more operational work. In exchange, you take a larger share of the per-unit margin and you control the product. Industry analyst Vern Christensen, writing in Nutraceutical Business Review, framed the channel dynamic this way: practitioner-channel brands push toward direct relationships and prescription-style recommendation models because formula control protects the brand from marketplace commodification.

What does not change: your relationship with the patient

The supplement is not the asset. The relationship is. Your patients trust your clinical judgment. They buy supplements you recommend because of that trust. The brand on the bottle is downstream of the trust, not the source of it.

This matters when you think about the transition. The risk of moving from dispensing to creating is not that patients will stop buying from you. If they have been buying the third-party version, they will likely buy the practitioner-branded version. The risk is operational: can your practice handle a branded SKU you own, with the inventory, returns, and quality-assurance work that comes with it?

Patients are loyal to practitioners. They are not loyal to brands. Your patient base does not need you to keep dispensing the brand they currently buy. They need you to keep being right about what they should take.

The business math

Dispensing a third-party brand through a distribution platform typically yields 30 to 50 percent margin on retail price. The platform handles fulfillment, inventory, and dispensing compliance overhead. You take a clean margin on each sale with no working capital tied up in physical product.

Creating your own brand changes the margin structure. A private-label SKU at 100 to 500 units MOQMOQ (Minimum Order Quantity)The smallest production run a manufacturer will accept for an order. runs $5 to $15 per unit cost of goods (depending on dosage form, ingredient profile, and packaging). Retail at $30 to $50 per unit is typical for practitioner-channel SKUs. That math suggests 60 to 80 percent gross margin per unit, but it does not account for the working capital you tie up in unsold inventory.

If you order 500 units at $10 per unit, you have committed $5,000 plus packaging and design costs. If patients buy 50 units a month, that capital sits on your shelves for 10 months. The 60 to 80 percent gross margin is real. The cash flow profile is harder than the third-party dispensing model.

This is why the first practitioner-created SKU is usually a product the practice already sells consistently from the third-party brand. Demand is validated. Inventory turns are predictable. The transition is a margin-improvement decision, not a market-creation decision.

The regulatory surface that becomes yours

Dispensing a third-party brand puts most regulatory responsibility on that brand. They are the labeler. They manage FDA registration. They handle adverse event reporting. They own structure-function claim compliance.

Creating your own brand transfers most of that regulatory surface to you. You become the labeler. You register with the FDA (or contract with a registered facility for production, which is the typical setup). You become responsible for any structure-function claim on the label. You become the entity an FDA warning letter targets if a claim is non-compliant.

This is manageable but not trivial. Several practitioner-channel brands have been issued FDA warning letters for structure-function claims that crossed into disease-treatment territory. The remediation cost in time, legal fees, and brand reputation is significant. Understanding the difference between "supports immune function" (allowed structure-function) and "treats colds" (disease claim, not allowed) is a load-bearing skill for a brand owner that was someone else's responsibility before.

For an introduction to the FDA structure-function claim envelope, see the IR structure-function claims guide. For the wider regulatory surface a first-time brand owner inherits, see supplement legal risks.

Timing considerations

The wrong time to create your own brand is when you are testing whether a category sells in your practice. Dispense the third-party version first. Generate 6 to 12 months of data on which SKUs your patients actually buy versus what they say they will buy.

The right time to create your own brand is when one or two SKUs from your dispensary turn over consistently and patients ask for refills without prompting. That signal is what custom inventory commitment requires.

Some practitioners run both models in parallel during transition. They keep dispensing third-party brands for SKUs they have not validated. They create their own brand for the one or two SKUs they have validated. Over 12 to 24 months, the share of revenue shifts toward the practitioner-branded SKUs. The third-party dispensing fills the gaps until a practitioner-branded equivalent justifies the inventory commitment.

What this transition does not replace

Creating your own supplement brand does not replace your clinical practice. It does not turn you into a manufacturer (you contract with a manufacturer). It does not turn you into a marketing agency (you continue to recommend based on clinical judgment). It does not turn you into a fulfillment operator if you choose a manufacturer or third-party logistics partner who handles dispensing.

It does add a business owner role to your existing practitioner role. You sign manufacturer contracts. You approve formulas. You manage inventory turns. You make pricing decisions. You face FDA compliance responsibility for your label. The practice still pays the bills. The brand becomes a margin-enhancement layer on top of the practice, not a replacement for it.

Frequently asked questions